Keyphrases
Acute Kidney Injury
19%
Albuminuria
11%
Arteriovenous Fistula
16%
Asia
15%
Balloon Angioplasty
16%
Chronic Kidney Disease
32%
Chronic Kidney Disease Patients
19%
Constipation
10%
COVID-19 Pandemic
8%
Diabetic Kidney Disease
25%
Dialysis
28%
Double-blind Randomized Controlled Trial
9%
Draining Vein
9%
End-stage Kidney Disease
10%
Etiology
9%
Fibroblast Growth Factor 23 (FGF23)
16%
General Hospital
10%
Hematuria
10%
Hemodialysis
30%
Hemodialysis Patients
20%
Hepatitis C
16%
Hypertension
19%
Indonesia
40%
Indonesian
19%
Indonesian Population
10%
Intensive Care Unit Patients
10%
International Society of Nephrology
10%
Jakarta
17%
Kidney Care
12%
Kidney Failure
21%
Kidney Replacement Therapy
14%
Liver Fibrosis
11%
Lupus Nephritis
9%
Maintenance Hemodialysis Patients
25%
Nephrin
16%
Nephrologists
8%
Nephrology
12%
Nigella Sativa Oil
8%
Peritoneal Dialysis
12%
Podocin
17%
Podocyte Injury
9%
Podocytopathy
9%
Quality of Life
16%
Risk Factors
20%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
16%
South Asia
9%
South-East Asia
18%
South-East Asia Region
9%
Type 1 Diabetes Mellitus (T1DM)
10%
Type 2 Diabetes Mellitus (T2DM)
11%
Medicine and Dentistry
2 Methyl 5 Trimethylammoniomethyl 1,3 Oxathiolane
8%
Acute Kidney Injury
18%
Adverse Event
8%
Albuminuria
11%
Arteriovenous Fistula
16%
Awareness
9%
Calcitriol
8%
Cardiology
8%
Cardiovascular System
12%
Chronic Kidney Disease
41%
Cohort Analysis
9%
Complications of Diabetes Mellitus
9%
COVID-19
19%
Creatinine
9%
Cross Sectional Study
17%
Diabetic Nephropathy
14%
Diagnosis
12%
Diagnostic Accuracy
8%
Disease Exacerbation
10%
Doxorubicin
14%
End Stage Renal Disease
16%
Fibroblast Growth Factor 23
16%
Glomerulopathy
16%
Health Care Cost
13%
Hematuria
10%
Hemodialysis
35%
Injury
11%
Ketoacidosis
8%
Lupus Nephritis
9%
Maturity Onset Diabetes of the Young
18%
Nephrin
17%
Nephrologist
9%
Nephrology
23%
Nephropathy
10%
Osmotic Nephrosis
10%
Outpatient
11%
Percutaneous Transluminal Angioplasty
16%
Peritoneal Dialysis
16%
Pneumoperitoneum
8%
Podocin
17%
Podocyte
18%
Prevalence
11%
Quality of Life
8%
Randomized Controlled Trial
9%
Renal Biopsy
11%
Renal Failure
30%
Renal Replacement Therapy
28%
Urinary System
11%
Urogenital Tract Infection
8%
Vasculotropin Receptor 2
8%
Pharmacology, Toxicology and Pharmaceutical Science
6 N,n' Dimethylarginine
16%
Acute Coronary Syndrome
8%
Adriamycin-Induced Nephropathy
8%
Binding Protein
8%
C Reactive Protein
8%
Calcium Carbonate
8%
Campylobacter Enteritis
8%
Chronic Hepatitis C
8%
Chronic Kidney Failure
50%
Constipation
9%
Cross-Sectional Study
29%
Diabetes Mellitus
9%
Diabetic Nephropathy
17%
End Stage Renal Disease
21%
Endotoxin
8%
Fibroblast Growth Factor 23
16%
Folic Acid
8%
Frailty
8%
Heart Failure
8%
Hematuria
8%
Hemodialysis
100%
Hepatitis C
16%
Homocysteine
8%
Indican
8%
Infection
11%
Khellin
8%
Kidney Failure
8%
Liver Cirrhosis
12%
Liver Fibrosis
16%
Major Adverse Cardiac Event
8%
Midazolam
8%
N(g),n(g) Dimethylarginine
16%
Nephrin
8%
Nigella sativa
8%
Placebo
9%
Podocin
10%
Prehypertension
8%
Prevalence
16%
Randomized Controlled Trial
18%
Replacement Therapy
8%
Synbiotic Agent
8%
Transferrin Receptor
8%
Uric Acid
8%
Vitamin B12
8%
Vitamin D Receptor
8%
